InSphero AG, Zurich, Switzerland
Jan Lichtenberg, Ph.D., is Co-Founder and CEO of InSphero AG. InSphero is the pioneer of 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. The company’s robust, precisely engineered suite of 3D InSight™ human tissue platforms are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. InSphero specializes in solutions for liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and oncology (with a focus on immuno-oncology and PDX models). The scalable Akura™ technology, which underlies these 3D InSight™ Discovery and Safety Platforms, includes 96- and 384-well plate formats as well as the Akura™ Flow organ-on-a-chip system. Dr. Lichtenberg started InSphero in 2009 and grew the company to 60+ employees in offices in Switzerland and the US. InSphero counts most of the global top 15 pharmaceutical and cosmetics companies amongst its customers. He holds a Ph.D. from the University of Neuchâtel and had a research group at the Swiss Federal Institute of Technology, Zurich. Jan serves also Vice President of SLAS.
Disclosure information not submitted.
Sunday, February 6, 2022
8:30 AM – 4:30 PM